Fig. 5From: Prognostic value of p16, p53, and pcna in sarcoma and an evaluation of immune infiltrationGene mutations in p16, p53, and pcna and their association with OS and DFS in patients with sarcoma (cBioPortal). High mutation rates of p16, p53, and pcna (61%) were observed in SARC patients, with mutation rates of 17, 50, and 6%, respectively (A). Relationship between genetic changes of p16, p53, and pcna and OS (B) and DFS (C) in SARC patientsBack to article page